Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanbei Zhuhan Capsule is a Traditional Chinese Medicine (TCM) botanical product being developed for the treatment of obstructive sleep apnea hypopnea syndrome (OSAHS). The drug is currently in Phase 3 clinical trials (e.g., CTR20221425) sponsored by Dongyang Baorentang Pharmaceutical. Clinical studies evaluate the efficacy of the capsules by measuring the response rate of the Apnea-Hypopnea Index (AHI) after four weeks of administration. As a herbal formulation, it is designed to address the underlying pathophysiology of sleep apnea, potentially through anti-inflammatory effects or by modulating airway patency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanbei Zhuhan Capsule (Dongyang Baorentang Pharmaceutical).